AesDex

Astex has developed multiple drugs now approved for market through partnerships, including ribociclib ("Kisqali"), erdafitinib ("Balversa"), and capivasertib ("Truqap"). Its own proprietary programs are in preclinical to late-stage clinical development, primarily targeting oncology and CNS diseases. The company’s fragment-based approach has led to productive collaborations with major pharmaceutical companies.

Several compounds from drug discovery collaborations with Astex have been advanced by Astex’s biopharma partners into clinical trials and onto the market...

Robust proprietary oncology portfolio with multiple drugs in mid-late stage clinical development...

Developing CNS portfolio of novel targeted therapeutics for defined neurodegenerative disease populations...

Productive partnerships with top-tier pharmaceutical companies...

Oncology and CNS Focused...leader in innovative small-molecule therapeutics...primary areas of focus are oncology and diseases of the CNS.

Approved partnered products include:

• ribociclib ("Kisqali") – CDK4/CDK6 inhibitor for breast cancer (with Novartis)
• erdafitinib ("Balversa") – FGFR inhibitor for metastatic urothelial carcinoma (with Janssen/J&J)
• capivasertib ("Truqap") – AKT inhibitor for HR-positive/HER-negative breast cancer (with AstraZeneca).